1 completed, 1 recruiting, 1 unknown, 1 withdrawn. 4 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 1, Recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 3 | Completed 1, Recruiting 1, Unknown 1 |
Follow Semaglutide Injectable Product: new trials by email Literature Review of Semaglutide Injectable Product trials Research Report on Semaglutide Injectable Product
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS) Metformin, Semaglutide Injectable Product - Polycystic Ovary Syndrome | Phase 2 / Phase 3 | Unknown | University of Hull | 60 | 2025-03-01 | 2024-05-10 |
| Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure Semaglutide Injectable Product, Calorie-restricted diet - Heart Failure With Reduced Ejection Fraction, Obesity | Phase 2 / Phase 3 | Recruiting | Jens D Hove, MD,PHD | 100 | 2024-04-30 | 2026-06-23 |
| Semaglutide in CFRD Semaglutide - Cystic Fibrosis, Cystic Fibrosis-related Diabetes | Phase 2 / Phase 3 | Completed | University of Minnesota | 8 | 2023-10-16 | 2026-01-21 |
| Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients Semaglutide Injectable Product, Placebo - Atrial Fibrillation, Overweight and Obesity | Phase 3 | Withdrawn | Axel Brandes | 2022-10-01 | 2023-11-03 |
Obesity (2) · Atrial Fibrillation (1) · Cystic Fibrosis (1) · Overweight (1) · Polycystic Ovary Syndrome (1) · Weight Loss (1)
Axel Brandes (1) · Jens D Hove, MD,PHD (1) · University of Hull (1) · University of Minnesota (1)
Denmark (1) · United Kingdom (1) · United States (1)
Amir Moheet, MBBS (1) · Axel Brandes, MD, DMSc (1) · Jens D Hove (1) · Morten L Hansen, MD, PhD (1) · Thozhukat Sathyapalan, MD, FRCP (1)
2023 (1)